News

The deal, which includes up to $26m option premium and R&D funding, grants Astellas an option to firstly negotiate an exclusive, worldwide license at the end of Phase

The ANDA product is a generic version of Gilead Sciences’ Letairis, which is designed to treat patients with pulmonary arterial hypertension (PAH). On 01 April 2015, Gilead and

Initially, the Japanese firm will develop NBI-98854 in Japan for the chorea associated with Huntington’s disease (HD) and tardive dyskinesia. Complete commercial rights to NBI-98854 in North America,

DDD107498 was developed as part of a collaboration between MMV and the University of Dundee Drug Discovery Unit, led by Prof Ian Gilbert and Dr Kevin Read. The

Due to the potential risk of osteosarcoma, Natpara is indicated only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. The

The drug is indicated for use in children and adolescents from four years of age who have had an inadequate response to or are inappropriate candidates for topical

Currently, the company is conducting a clinical trial of IMO-8400 in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation. The company said that preclinical trials

UCB’s established products business will cover the territories of India, Nepal, Sri Lanka and Maldives. The acquisition of UCB’s existing established brands in India, including its franchises in

In order to close the merger, Valeant offered a $173 per Salix share, which is an increase from a bid of $158 per share in cash made this